A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.

Chi, K N

A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology Apr 2008 - 746-51 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1569-8041

10.1093/annonc/mdm554 doi


Administration, Oral
Aged
Aged, 80 and over
Angiogenesis Inhibitors--administration & dosage
Antineoplastic Agents--administration & dosage
Antineoplastic Agents, Hormonal--therapeutic use
Benzenesulfonates--administration & dosage
Biomarkers, Tumor--analysis
Canada
Cell Proliferation--drug effects
Disease Progression
Disease-Free Survival
Drug Administration Schedule
Drug Resistance, Neoplasm
Humans
Immunohistochemistry
Kaplan-Meier Estimate
Lymphatic Metastasis
Male
Middle Aged
Neoplasms, Hormone-Dependent--blood supply
Neovascularization, Pathologic--drug therapy
Niacinamide--analogs & derivatives
Phenylurea Compounds
Prostate-Specific Antigen--blood
Prostatic Neoplasms--blood supply
Protein Kinase Inhibitors--administration & dosage
Pyridines--administration & dosage
Sorafenib
Treatment Outcome